English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/100154
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 8 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells

Autor González-Vallinas, Margarita; Molina, Susana; Vicente, G. ; Sánchez-Martínez, Ruth; Vargas, Teodoro; García-Risco, Mónica R.; Fornari, Tiziana ; Reglero, Guillermo ; Ramírez de Molina, Ana
Palabras clave Estrogen receptor alpha
Human epidermal growth factor receptor-2
Paclitaxel
Rosemary
Breast cancer
Fecha de publicación 2014
EditorWiley-VCH
Citación Electrophoresis 35(11): 1719-1727 (2014)
ResumenBreast cancer is the leading cause of cancer-related mortality among females worldwide, and therefore the development of new therapeutic approaches is still needed. Rosemary (Rosmarinus officinalis L.) extract possesses antitumor properties against tumor cells from several organs, including breast. However, in order to apply it as a complementary therapeutic agent in breast cancer, more information is needed regarding the sensitivity of the different breast tumor subtypes and its effect in combination with the currently used chemotherapy. Here, we analyzed the antitumor activities of a supercritical fluid rosemary extract (SFRE) in different breast cancer cells, and used a genomic approach to explore its effect on the modulation of ER-α and HER2 signaling pathways, the most important mitogen pathways related to breast cancer progression. We found that SFRE exerts antitumor activity against breast cancer cells from different tumor subtypes and the downregulation of ER-α and HER2 receptors by SFRE might be involved in its antitumor effect against estrogen-dependent (ER+) and HER2 overexpressing (HER2+) breast cancer subtypes. Moreover, SFRE significantly enhanced the effect of breast cancer chemotherapy (tamoxifen, trastuzumab, and paclitaxel). Overall, our results support the potential utility of SFRE as a complementary approach in breast cancer therapy. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
URI http://hdl.handle.net/10261/100154
DOI10.1002/elps.201400011
Identificadoresdoi: 10.1002/elps.201400011
e-issn: 1522-2683
issn: 0173-0835
Aparece en las colecciones: (CIAL) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.